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Abstract 
One of the earliest neuropathological events in Alzheimer’s disease is accumulation of astrocytes 
at sites of Aβ1-42 depositions. Our results indicate that Aβ1-42 toxic peptide increases lipid pe-
roxidation, apoptosis and cell death in neurons but not in astrocytes in primary culture. 
Aβ1-42-induced deleterious neuronal effects are not present when neurons and astrocytes are 
mixed cultured. Stimulation of astrocytes with toxic Aβ1-42 peptide increased p-65 and decreased 
IκB resulting in inflammatory process. In astrocytes Aβ1-42 decreases protein expressions of sirtuin 
1 (SIRT-1) and peroxisome proliferator-activated receptor γ (PPAR-γ) and over-expresses 
peroxisome proliferator-activated receptor γ coactivator 1 (PGC-1) and mitochondrial tran-
scription factor A (TFAM), protecting mitochondria against Aβ1-42-induced damage and pro-
moting mitochondrial biogenesis.  
In summary our data suggest that astrocytes may have a key role in protecting neurons, increasing 
neural viability and mitochondrial biogenesis, acquiring better oxidative stress protection and 
perhaps modulating inflammatory processes against Aβ1-42 toxic peptide. This might be a sign of a 
complex epigenetic process in Alzheimer’s disease development. 
Key words: Alzheimer’s Disease, MnSOD, PPAR-γ, TFAM, PGC-1, NF-κB. 
Introduction 
The metabolic processing of the amyloid pre-
cursor protein (APP) produces mainly two peptide 
fractions of amyloid β peptide (Aβ), Aβ1-40 and Aβ1-42. 
The accumulation and precipitation of Aβ1-42 peptide 
has been suggested as a neuropathological event as-
sociated with the progress and development of Alz-
heimer's disease (AD) [1, 2]. Extracellular Aβ1-42 de-
posits can cause oxidative stress, inflammation and 
mitochondrial dysfunction [3, 4, 5]. It has been shown 
in vitro and in vivo studies that the Aβ1-42 enters the 
mitochondria causing an increase in reactive oxygen 
species, interruption of the electron transport chain 
and blockade of the ATP production [6, 7]. A defi-
ciency in the function of the mitochondrial respiratory 
chain could affect the survival of cells associated with 
AD resulting in adverse impact for long-term health 
[8]. Moreover extracellular Aβ1-42 peptide induces 
oxidative stress and causes damage to mitochondrial 
DNA (mtDNA) which encodes the 13 key subunits of 
the respiratory chain, essential for respiratory func-
tion, susceptible to oxidative damage [9,10]. The 
mtDNA maintenance, including nucleotide formation 
as well as mtDNA stabilization and transcription is in 
charge of mitochondrial transcription factor A (TFAM) 
[11]. Recent studies have indicated that TFAM and 








ROS generation and improve mitochondrial respir-
atory function [12, 13]. Furthermore over-expression 
of TFAM has been shown protect mitochondria 
against Aβ-induced oxidative damage in neurons [14]. 
Glial cells interact with Aβ1-42 and support 
neurons, but whether astrocytes could participate in 
regulating the Aβ-induced brain damage is, at the 
moment, poorly known. Here we evaluated the role 
of astrocytes in the neuro-toxic effects of Aβ peptides. 
For this purpose we used pr i ma ry  a strocytes, 
neurons and mixed-cultures in the absence and in 
the presence of toxic Aβ1-42 peptide or non-toxic Aβ40-1 
(control) peptide. Our results demonstrate that Aβ1-42 
(5 µM) induces apoptotic cell death in neurons. 
However in mixed-cultures, astrocytes protect 
neurons against Aβ1-42-induced toxicity. Mechanis-
tically astrocytes-induced neuron protection involves 
over-expression of TFAM and PGC-1, and decrease in 
PPAR-γ and SIRT-1. 
Experimental Procedures 
Materials 
   3-(4,5-dimethyl-2-thiazolyl)-2,5-dipheniyl-2H- 
tetrazolium bromide (MTT) was obtained from Sigma 
Chemical Co. (St Louis, MO). Dulbecco’s modified 
Eagle’s medium (DMEM) and foetal bovine serum 
(FBS) were obtained from Gibco (Gibco Invitrogen 
Corporation, Barcelona, Spain). Western Blot 
Chemiluminescent Detection System (ECL) was from 
Amersham (Amersham Biosciences, Barcelona, 
Spain). Antibodies: monoclonal anti-cytochrome c 
antibody (anti-Cytochrome c) (1:500), polyclonal 
anti-manganese superoxide dismutase (anti-MnSOD) 
(1:250), monoclonal anti-p65 (1:250), monoclonal anti- 
PGC-1 (1:250), monoclonal anti-TFAM (1:250), 
monoclonal anti-IκB (1:250), polyclonal anti-PPAR-γ 
(1:300), monoclonal anti-SIRT-1 (1:250), and mono-
clonal anti-tubuline (1:3000) antibodies (Sigma 
Aldrich, Madrid, Spain) were used. All other reagents 
were of analytical or culture grade purity. The oligo-
mers Aβ (40-1 and 1-42), were prepared following 
manufacture instructions such as indicates Sig-
ma-Aldrich biotechnology. Briefly, the peptides were 
dissolved in H2O and for assembly the oligomer 
preparations were heated for 24 h at 37ºC.  
Primary culture of cortical astrocytes 
All animals were handled according to the rules 
established by the bioethics committee of the School 
of Medicine, University of Valencia, Spain. Cerebral 
cortical astrocytes were isolated from rat fetuses of 21 
days gestation. Fetuses were obtained by cesarean 
section and decapitated. Cerebral cortices were re-
moved and cut into 1mm cubes and triturated 10–15 
times through a Pasteur pipette. After centrifugation 
at 1000 rpm for 5 min the pellet was resuspended in 
DMEM containing 20% fetal bovine serum (FBS), 
supplemented with L-glutamine (1%), HEPES (10 
mM), fungizone (1%), and antibiotics (1%). Cells were 
plated on T75 culture flask pretreated with 
poli-L-lysine. Cultures were maintained in a humidi-
fied atmosphere of 5% CO2/95% air at 37°C and 
allowed to grow to confluence and used at 15-20 days 
in vitro. After 1week of culture, the FBS content was 
reduced to 10%, and the medium was changed twice a 
week. The purity of astrocytes was assessed by 
immunofluorescence using anti-glial fibrillary acidic 
protein (anti-GFAP, astrocyte marker: Sigma-Aldrich, 
Madrid, Spain), anti-CD-68 (microglial marker: Sero-
tec, Kidlington, UK), anti-myelin basic protein (oli-
godendroglial marker; Sigma-Aldrich, Madrid, Spain) 
and anti- microtubule-associated protein 2 (an-
ti-MAP2, neuronal marker; Sigma-Aldrich, Madrid, 
Spain). The astrocytes were found to be at least 99% 
glial fibrillary acidic protein positive. No cells were 
found to express CD-68, myelin basic protein or 
microtubule-associated protein-2. For all of the ex-
periments we used toxin-free sterile culture materials. 
Neurons and neurons-astrocytes mixed 
cultures 
Cerebral cortical neurons were isolated from rat 
fetuses of 14 or 15 days gestation. Briefly, cerebral 
cortices were removed and dissociated mechanically, 
by pipetting 10 times with 10ml DMEM. The cell 
suspension was filtered through nylon mesh with a 
pore size of 90 μm. Cell suspension was plated on 
T75 culture flask pretreated with poli-L-lysine. After 
attachment of the cells, the culture medium was 
changed to DMEM containing 10% FBS supplemented 
with antibiotics (1%) and fungizone (1%). Cultures 
were grown in a humidified atmosphere of 5% 
CO2/95% air at 37ºC. After 3 days, cells were exposed 
to 10 μM cytosine β-D arabino-furanoside for 24 h to 
inhibit proliferation of non-neuronal cells. The purity 
of neurons and possible contamination by astrocytes 
were assessed by immunofluorescence using anti-
bodies anti-GFAP and anti-MAP-2. Under these 
conditions, 99% of the cells were neurons. Mixed 
cultures cells were not exposed to cytosine β-D arab-
ino-furanoside allowing the proliferation of 
non-neuronal cells.  Ten days after seeding ap-
proximately 60% of cells were astrocytes and 40% 
neurons. At this time, 5 μM Aβ1-42 (toxic) or Aβ40-1 
(control) were added and assays were performed at 
indicated times. Treatment of cultures with Aβ40-1 did 
not produce any effects compared with cultures in the 
absence of any peptide (data not shown). 





Cell viability of the cultures was determined by 
the MTT assay [15]. Neurons and/or astrocytes were 
plated in 96 well cultures. Aβ40-1 (control) and Aβ1-42 
peptides were added to wells during 24h. After cell 
treatments the medium was removed and the cortical 
cells were incubated with red free medium and MTT 
solution [0.5 mg/ml, prepared in phosphate buffer 
saline (PBS) solution] for 4 h at 37ºC. Finally the 
medium was removed and formazan particles were 
dissolved in dimethyl sulfoxide (DMSO). Cell viabil-
ity, defined as the relative amount of MTT reduction 
was determined by spectrophotometry at 570 nm.  
Caspase-3 activity assay 
Caspase activity was performed with the Apo 
Alert CPP32/caspase 3 assay kit according to the 
manufacturer’s protocol (CLONTECH, Palo Alto, 
CA). Adherent cells were collected, centrifuged and 
washed twice with ice-cold PBS and stored as a pellet 
at -80 ºC. Cell pellets were solubilised in lyses buffer 
and centrifuged to remove debris and samples con-
taining equal amounts of protein were incubated with 
50 μm N-acetyl-Asp-Glut-Val-Asp-AFC (7-amino-4- 
trifluoromethyl coumarin) 1h at 37ºC. The samples 
were analyzed using an enzyme-linked immuno-
sorbent assay plate reader with excitation of 360 nm 
and emission of 530 nm. 
Malondialdehyde determination 
Malondialdehyde (MDA) levels were assessed 
by high-performance liquid chromatography. Cells 
were homogenized and centrifuged, and the super-
natants collected and stored on ice. Samples were 
hydrolyzed by boiling in diluted phosphoric acid. 
MDA, one of the low- molecular weight end products 
formed by lipid-peroxidation, reacted with thiobar-
bituric acid (TBA) to form MDA-TBA adducts which 
were eluted with methanol-phosphate buffer to be 
quantified by spectrophotometry at 532 nm. 
Western blot analysis 
Cultured cells were treated with lysis buffer and 
then mechanically degraded to release the proteins. 
Protein concentration was determined using modified 
Lowry method [16]. Loading buffer (0.125 M 
Tris-HCl, pH 6.8, 2% SDS, 0.5% (v/v) 
2-mercaptoethanol, 1% bromophenolblue and 19% 
glycerol) was added to protein sample and heated for 
5 min at 95ºC. Proteins were separated on SDS-PAGE 
gels and transferred to nitrocellulose membranes in a 
humid environment using a transfer buffer (25 mM 
Tris, 190 mM glycine, 20% methanol). Membranes 
were blocked with 5% milk in TBS (0.05% Tween-20) 
and were incubated with primary antibodies over-
night at 4ºC. Membranes were washed 3 times with 
wash buffer TBS-T (TBS, 0.2% Tween-20) and were 
incubated with a secondary anti-rabbit IgG or an-
ti-mouse IgG (Cell Signalling Technologies Danvers, 
MA) antibody conjugated to the enzyme horseradish 
peroxidase (HRP) for 1 h. Membranes were washed 
three times and proteins were detected using the ECL 
method as specified by the manufacturer. Autoradi-
ography signals were assessed using digital image 
system ImageQuant LAS 4000 (GE Healthcare). 
Peroxide levels determination 
To determine peroxide levels we used a modifi-
cation of the method described by Barja et al. [16]. 
Cells were washed twice with PBS and then incubated 
at 37ºC with a PBS solution containing 0.1 mM 
homovanilic acid and 6 U/ml horseradish peroxidase. 
Incubation was stopped at 5 min with cold glycine 
buffer (2M) containing 50 mM EDTA and 2.2 M 
NaOH. Supernatant was measured by fluorescence 
(312 nm excitation and 420 nm emission). 
Statistical methods 
Values are expressed as mean ± S.D. Differences 
between groups were assessed by one-way analysis of 
variance (ANOVA). Statistical significance was ac-
cepted at P ≤ 0.05. Data sets in which F was significant 
were examined by a modified t-test. 
Results 
Astrocytes protect neurons from Aβ-induced 
cell death. 
As a first step we evaluated Aβ-induced cell 
death in cultured neurons and/or astrocytes. As 
shown in Figure 1, treatment with Aβ1-42 peptide (5 
μM 24 hours) caused a decrease in cell viability of 
about 50% compared with control neurons. However, 
treatment of astrocytes with the toxic peptide did not 
induce any significant changes in cell viability 
compared with control untreated astrocytes. 
Moreover, when neurons and astrocytes were 
mixed-cultures we did not detect neuron cell death 
after toxic peptide addition as compared with 
controls.  
Aβ increases caspase 3 levels in neurons 
treated with Aβ toxic peptide. 
In order to investigate if these changes were 
part of an ongoing apoptotic process, we evaluated 
the effect of toxic Aβ1-42 treatment on activation of a 
late-effector caspase. In vitro activity of DEVDase 
caspase was assayed after treating cells with Aβ1-42 
toxic peptide, and Aβ40-1 as a control peptide. As 
shown in Figure 2, the presence of the toxic peptide 
resulted in almost a 3 times increase in DEVDase 




caspase activity in primary cultured neurons, 
without significant changes in astrocytes or in 
mixed-culture cells, demonstrating apoptosis induc-
tion only in isolated neurons. One of the recep-
tor-mediated mechanisms linked to activation of late 
caspases involves mitochondrial dysfunction, 
characterized by release of cytochrome c  and 
subsequent activation of caspase 9 [17]. As shown in 
Figure 2, indeed Aβ1-42 causes cytochrome c release in 
cultured neurons. 
Aβ increases lipid peroxidation in neurons in 
primary culture. 
Aβ causes neurone cell death; likely by inducing 
caspases-dependent apoptosis (Figure 2), we also 
measured if this toxicity was  associated with oxi-
dative stress. For this purpose MDA levels were 
measured as a marker of lipid peroxidation. Aβ1-42 (5 
µM x 24h) increased MDA levels in cultured neurons 
(Figure 3) as compared to controls. However the 
presence of Aβ1-42 did not modified either MDA levels 
in astrocytes or in mixed-culture cells (Figure 3). Only 
at higher concentrations of toxic peptide ≥ 20 µM we 
detected an increase of MDA levels in primary cul-




Figure 1. Aβ1-42 induces loss 
of cell viability in neurons 
but not in astrocytes and in 
mixed-culture cells. Cell 
viability was determined by MTT 
assay in cells treated for 24 h 
with 5 μM Aβ40-1 (control, C) or 
5 μM Aβ1-42 (Aβ). Data are 
mean ± SD of four independent 








Figure 2. In vitro DEVDase caspase-3 activity assay in astrocytes, neurons and mixed-culture cells. DEVDase caspase-3 activity was evaluated after 
24 h incubation with 5 μM Aβ40-1 as a control (C) or Aβ1-42 as a toxic peptide (Aβ) in neurons, astrocytes and in mixed-culture cells. The results are representative 
of four independent experiments in quadruplicate. *P < 0.04 vs. control cells. Western-blot with Cytochrome c  was evaluated in primary culture neurons. 
Data are mean ± SD of five independent experiments. *P < 0.05 vs. control. 






Figure 3. MDA levels in 
neurons, astrocytes and 
mixed-culture cells. 
Cells were treated for 24 h 
with 5 μM Aβ40-1 (control, 
C) or 5 μM Aβ1-42 (Aβ). 
Data are mean ± SD of 
three different experiments. 












Aβ causes mitochondrial biogenesis in primary 
cultured of astrocytes. 
Figure 4 shows a significant increase in mito-
chondrial biogenesis in astrocytes incubated with the 
toxic peptide as compared to control. Panel A 
contains green images which are dispersed all over 
the astrocytes, whereas panel B displays brighter 
green spots which correspond to mitochondrial bi-
ogenesis (mitotracker). The blue dots in the images 
correspond to nuclei stained with Hoechst 33342. 
Panel E shows an immunofluorecent with Tom-20 
antibody in control cells and in presence of Aβ1-42 
peptide (panel F). The most immunofluorescent pre-
sent in panel F indicates an increase in mitochondrial 









Figure 4. Aβ1-42 increases mitochondrial aggregation in astrocytes in primary culture. Mitochondrial aggregation induced by Aβ1-42 was determined 
by confocal microscopy in astrocytes in primary culture treated for 6 h with 5 μM Aβ40-1 (C) or 5 μM Aβ1-42 (Aβ). Fluorescence products used were: Mitotracker 
(250 nM) to stain mitochondria and Hoechst 33342 (2 μg ml–1) to stain nuclei (A, B). Contrast image (C, D). Immunofluorescence was used with Tom 20 (E, F; 
1:1000). Bar represents 20 μm. 





Figure 5. Increase of peroxide levels, p-65 subunit (NF-κB), MnSOD, and IκB expressions caused by Aβ1-42 in astrocytes in primary culture. 
Peroxide levels were determined in cells treated for 24 h with 5 μM Aβ40-1 (C) or 5 μM Aβ1-42 (Aβ). Data are mean ± SD of three different experiments. 
*P < 0.01 vs. control. p-65, MnSOD and IκB protein expressions were determined in control conditions(C) and after addition of 5 μM toxic peptide Aβ1-42 during 
24 h (Aβ). Data are mean ± SD of four independent experiments. *P < 0.05 vs. control.  
 
Figure 6. Aβ1-42 increases TFAM and PGC-1 and decreases PPAR-γ and SIRT-1 protein expressions in astrocytes in primary culture. Astrocytes 
were incubated with 5 μM of Aβ1-42 (Aβ) or 5 μM Aβ40-1 (C) for 24 h and collected to determine TFAM, PGC-1, PPAR-γ and Sirt-1 protein expressions by western 
blot. A representative immunoblot is shown in the top panel. Data are mean ± SD of four independent experiments. *P < 0.05 vs. control. 





Aβ1-42 increases peroxide levels, MnSOD and 
p-65 (NF-κB) protein expressions in primary 
cultured astrocytes. 
To know whether astrocytes in primary culture 
present oxidative stress, we determined peroxide 
levels. After 24 h of incubation with Aβ1-42, we 
detected an increase of H2O2 levels in astrocytes in 
primary culture. Moreover, we also observed an 
important increase of MnSOD protein expression 
induced by ROS in cultured astrocytes (Figure 5), 
demonstrating an oxidative stress induction. We 
detect the nuclei-levels of p-65 protein, component of 
NF-κB in Figure 5 demonstrating an increase in p-65 
protein expression in astrocytes after toxic peptide 
addition during 24 h. Furthermore, we noted a de-
crease in IκB protein level from cytoplasm astrocytes. 
Both results indicate that Aβ1-42 increases NF-κB pro-
tein expression in astrocytes. 
Aβ1-42 addition produced increase of TFAM 
and PGC-1 and decrease expression in PPAR-γ 
and SIRT-1 in primary cultured astrocytes.  
As mitochondrial biogenesis induction occurs, 
we determined the levels of TFAM and PGC-1 in the 
absence (control) and in the presence of Aβ1-42. 
Toxic peptide induces protein overexpression of 
TFAM and PGC-1 in astrocytes. TFAM and PGC-1 
proteins are related with mitochondrial biogenesis in 
cells after mitochondrial stress. Figure 6 also shows a 
significant decrease in PPAR-γ (an anti-inflammatory 
protein) and SIRT-1 after treatment with Aβ1-42.  
Discussion 
The results of the present study show that Aβ1-42 
peptide diminishes cellular viability, increases apop-
tosis and lipid peroxidation in neurons but neither in 
astrocytes nor mixed-culture. These findings indicate 
a protective role of astrocytes on neurons against 
Aβ1-42 toxic peptide. The results also demonstrate that 
astrocytes increase mitochondrial biogenesis and 
MnSOD protein expression; both mechanisms can 
contribute to the protective role of astrocytes. Rela-
tionship between neurons and astrocytes will be 
important to understand brain development and/or 
neurodegeneration. In brain from AD patients both 
inflammation and oxidative stress are increased [17], 
but their pathogenic significances remain unclear. 
Because anti-inflammatory therapy protects neurons 
against toxic substances [18], keep down inflamma-
tion and oxidative stress processes could improve 
neurodegeneration in AD. It is known that astrocytes 
have nutritional and support functions to neurons but 
also astrocytes can protect them against oxidative 
stress and inflammation [19, 20]. This protective effect 
may become deleterious when the activation of as-
trocytes increases [21]. Our results indicate that Aβ1-42 
significantly increases MDA levels in neurons in pri-
mary culture without any changes in primary culture 
of astrocytes and mixed culture. Since MDA indicates 
lipid peroxidation, a reduction in MDA levels in 
mixed cultures is consistent with a protective effect of 
astrocytes against lipid peroxidation.  
The presence of astrocytes in the mixed cultures 
might protect neurons to inflammation and oxidative 
stress caused by Aβ1-42, as authors published for other 
toxic components [22]. Carrero et al. [23] suggest that 
reactive astrocytes might be mediated by pro- and/or 
inflammatory gene expression and NFκB increase, 
which would potentiate neuronal demise. In this 
study, Aβ peptide induces damage by simple injec-
tion affecting neurons, astrocytes and blood vessels. 
The differences with Carrero et al. could be due to the 
different methodology used. Our experiments, carried 
out in cultured cells, allow us to study the effects of 
Aβ peptide on neurons, astrocytes or mixed-cultures 
selectively. Thus we could assess whether the neu-
ronal damage is caused by direct effect of Aβ1-42 pep-
tide or by inflammation generated in other cells. 
Moreover, increase of p-65 protein expression in as-
trocytes observed in our study could not indicate a 
neuronal demise but probably a protection of neu-
rons. Although there is evidence that inflammation 
promotes AD, certain inflammatory mediators may 
also improve AD [20]. Wyss Corey et al. published the 
role of astrocytes such as defence cells inside the 
brain, and indicating a phagocyte process of astro-
cytes to eliminate and destroy Aβ peptide [20]. Our 
previous study also demonstrated the an-
ti-inflammatory effects of astrocytes after 
Aβ-induction and protection with genistein or estra-
diol [6]. 
Furthermore, in cultured astrocytes we observed 
that Aβ1-42 upregulated MnSOD expression suggest-
ing a possible antioxidant defence system that could 
protect neurons against oxidative damage scavenging 
ROS, such as occurs inside the brain [24]. Our results 
indicate that astrocytes protect neurons probably by 
an increase in mitochondrial biogenesis, obtaining 
better oxidative stress protection and perhaps pro-
ducing control of inflammatory process. Increase 
reactive oxygen species is involved in mitochondrial 
DNA injury [9]. It is well known that TFAM induces 
mitochondrial DNA replication and maintenance 
[11]. In cultured SH-SY5Y cells, over-expression of 
TFAM diminished reactive oxygen species production 
and attenuated Aβ1-42-induced cell damage [25]. Ac-
cordingly, our results demonstrate an induction of 
p-65 (NF-κB) and over-expression of TFAM and 
PGC-1 after Aβ1-42 peptide addition in astrocytes in 




primary culture. Data indicate that mitochondrial 
biogenesis can be involved in neuronal protection 
against Aβ1-42 toxic peptide. These effects can be done 
by TFAM because over-expression of TFAM in 
astrocytes probably produces protection of mtDNA 
against Aβ1-42 peptide. TFAM can protect mtDNA 
from oxidative stress and inflammation by covering 
the mtDNA region [11, 13] as well as maintaining 
mtDNA copy number [26] .  Furthermore, TFAM 
could increase mitochondrial biogenesis controlling 
mitochondrial dysfunction by initiate mtDNA tran-
scription [27].  
SIRT-1 has a role on deacetylate reactions of dif-
ferent proteins such as transcription factors involved 
in metabolic regulation, stress modulation, cell sur-
vival, aging and immune or inflammatory processes 
[28]. Expression of sirtuins is increased in caloric re-
striction of brain tissue [29] and a significant decrease 
in SIRT-1 protein has been noted in AD patients [30]. 
SIRT-1 modulates PGC-1 transcriptional expression 
and NF-κB activity in rat cardiac tissue [31]. Up or 
downregulation of PGC-1 determinates mitochondrial 
biogenesis through TFAM [32]. In our results, Aβ1-42 
decreases SIRT-1 protein expression in cultured as-
trocytes which upregulates PGC-1 and TFAM result-
ing in augmentation of mitochondrial biogenesis. On 
the other hand we observed that Aβ1-42 diminishes 
PPAR-γ expression leading to an increase of NF-κB 
expression. This factor promotes PGC-1 phosphoryla-
tion that raises TFAM resulting in mitochondrial bi-
ogenesis (Figure 7). Taken together, our results indi-
cate that Aβ1-42 exposition induces mitochondrial bi-
ogenesis in cultured astrocytes.  
 
 
Figure 7. Signalling in astrocytes in primary culture after Aβ1-42 
addition. The axis PGC-1-TFAM-Mitochondrial Biogenesis is regulated by 
PPAR-γ, NF-κB, SIRT-1 and MnSOD. Aβ1-42 toxic peptide decreases SIRT-1 and 
PPAR-γ and increases MnSOD and NF-κB leading to PGC-1-TFAM 
up-regulation resulting in mitochondrial biogenesis. 
 
Astrocytes are involved in brain homeostasis, 
neural function, metabolic support to neurons and 
also in the synthesis of glutathione and its precursors 
[33]. The exact mechanisms as astrocytes protect 
neurons remain to be determined. Qin et al. have re-
ported that mitochondrial biogenesis is altered in AD 
[34]. Because the presence of astrocytes prevents 
neuronal lipid peroxidation induced by Aβ1-42, we can 
hypothesize that increase of mitochondrial biogenesis 
in astrocytes supply high-energy demand to diminish 
free radical release induced by Aβ1-42 peptide. There-
fore this mechanism could protect neurons against 
lipid peroxidation increase (Figure 7). 
In conclusion, our results indicate that astrocytes 
may have a key role in protecting neurons against 
Aβ1-42 toxic peptide by increasing cell viability and 
mitochondrial biogenesis, obtaining better oxidative 
stress protection and perhaps modulating inflamma-
tory processes. This might be a sign of a complex ep-
igenetic process in Alzheimer’s disease development. 
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